Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs RLX Technology Inc (RLX) Price & Performance

BridgeBio Pharma IncTrade
RLX Technology IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs RLX Technology Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while RLX Technology Inc trades at $1.98 (market cap $2.42B). The key difference: BridgeBio Pharma Inc is far larger — about 6.8× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5.05% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIORLX
Market Cap
$16.36B$2.42B
Sector
HealthTechnology
52-Week High
$90.17$2.73
52-Week Low
$47.29$1.79
Enterprise Value
$18.14B$1.04B
Dividend Yield
5.05%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About RLX Technology Inc

RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.

Read more on RLX